Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMG 108 in rheumatoid arthritis
NCT00369473Phase 2Completed
- Sponsor
- Amgen
- Start
- Sep 2006
- Primary completion
- Jun 2008
- Modality
- Monoclonal Antibodies
01
Overview
Phase 2, randomised, double-blind trial of AMG 108 in rheumatoid arthritis (RA) (2 arms), sponsored by Amgen. Primary endpoint: Long-term safety at 144 weeks. Started Sep 2006; status: completed.
02
Drugs
AMG 108
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT00369473.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00369473.